Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis

Batten Disease Clinical Trial

Official title:

Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01035424
• Other study ID #: 0901010186
• Secondary ID: U54NS065768R01NS
• Status: Completed
• Start date: June 2009
• Est. completion date: January 2016

Study information

• Verified date: July 2020
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary aim of the study is to assess the genotype - phenotype correlations of the CNS manifestations of late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal, rare, recessive disorder of the CNS in children. This study will be accomplished by comparing the genotype to a neurologic assessment and Weill Cornell LINCL scale, the UBDRS scale, the standardized CHQ quality of life scale, and the Mullen scale; magnetic resonance imaging (MRI); and routine clinical evaluations. This study is designed to run parallel to a separate study which is being done by the Department of Genetic Medicine, which will use gene transfer to treat the central nervous system (CNS) manifestations of late infantile neuronal ceroid lipofuscinosis.

Description:

This protocol is designed to study the natural disease process of LINCL. We propose to assess the correlation between genotype (genetic constitution) and phenotype (observable characteristics) of late infantile neuronal ceroid lipofuscinosis (LINCL) in children diagnosed with LINCL in all stages. LINCL is a form of Batten disease that affects the brain of children and prevents it from functioning properly. These children are born with genetic changes called mutations that result in the inability of the brain to properly recycle proteins in the brain. The recycling failure leads to death of the nerve cells in the brain and progressive loss of brain function. Children with Batten disease are normal at birth but by age 2 to 4 have motor and vision problems which progress rapidly to death at age approximately 10 years old. There are no therapies available to treat the disease. This study is designed to run parallel to the gene transfer protocol, which will include 16 individuals in two groups: Group A will receive 9.0x10^11 genome copies (gc) of the vector and Group B will receive 2.85x10^11 gc; we anticipate that we will be able to capture a one-time genotype - phenotype snapshot for all n=32, and an 18 months genotype - phenotype progression assessment for n=16.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria.

1. Definitive diagnosis of LINCL, based on clinical phenotype and genotype.

2. The subject must be between the age of 2 and 18 years.

3. The subject will not previously have participated in a gene transfer or stem cell study.

4. Parents of study participants must agree to comply in good faith with the conditions of the study, including attending all of the required baseline and follow-up assessments, and both parents or legal guardians must give consent for their child's participation.

Exclusion criteria.

1. Presence of other significant medical or neurological conditions may disqualify the subject from participation in this study e.g.,malignancy, congenital heart disease, liver or renal failure.

2. Subjects without adequate control of seizures.

3. Subjects with heart disease that would be a risk for anesthesia or a history of major risk factors for hemorrhage.

4. Subjects who cannot participate in MRI studies.

5. Concurrent participation in any other FDA approved Investigational New Drug.

6. Subjects with history of prolonged bleeding or abnormal platelet function or taking aspirin.

Related Conditions & MeSH terms

• Batten Disease
• Late Infantile Neuronal Ceroid Lipofuscinosis
• Neuronal Ceroid-Lipofuscinoses

Locations

Country	Name	City	State
United States	Weill Cornell Medicine	New York	New York

Sponsors (4)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Rare Diseases Clinical Research Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Weill-Cornell LINCL scale at 18 months	The Weill Cornell LINCL scale, a 12 point scale which combines assessment of feeding, gait, motor and language to give an overall assessment of various CNS functions	Day 0, 18 months
Primary	Change in MRI parameters at 18 months	MRI assessment at various intervals Day 0 and month 18. Based on previous analyses, we have determined that 3 imaging parameters (% grey matter volume, % ventricular volume and cortical apparent diffusion coefficient) correlate best with age and with the Weill Cornell LINCL scale. These 3 imaging parameters will be used to assess disease progression in this screening protocol and the effect of the gene transfer in the IRB approved gene transfer trials (IRB #0810010013 and #1005011054). For those children available to continue in the study, all parameters will be re-assessed by comparing baseline evaluations to month 18 evaluation.	Day 0, 18 months
Secondary	Change in CHQ or ITQoL	Quality of life questionnaires which will be completed by at least one parent/legal guardian at the time of the LINCL patients' visits to Weill Cornell16,17; we will administer either survey depending on the age of the subject independently to each parent to minimize observer bias if both parents are present.	Day 0, 18 months
Secondary	Change in Mullen Scale	A pediatric developmental psychological rating scale	Day 0, 18 months